Menu
Loading...
  • Tuesday 2 October 2018

    New Glenmark paper: TLA and clonal derivation assessment of (CHO) cell lines

    In a recent paper published in the journal of Biotechnology, Glenmark Pharmaceuticals S.A. describes the use of the TLA technology in the analytical assessment of clonal derivation of cell populations.


    Read more...
  • Thursday 13 September 2018

    Cergentis & Princess Máxima Center collaborate on MRD test development for leukaemia and solid tumours

    Cergentis & the Princess Máxima Center for pediatric oncology (the specialised national center for care, cure and research of children with cancer in the Netherlands) have initiated various collaborations in which breakpoint sequences identified with Cergentis’ TLA Technology are used for the design of sensitive & quantitative minimal residual disease (MRD) and/or circulating tumour DNA tests.

    Cergentis & Princess Máxima Center collaborate on MRD test development for leukaemia and solid tumours
    Read more...
  • Monday 13 August 2018

    New Harvard paper on the importance of mapping transgene integration sites

    A new paper, published by the Sanes lab of Harvard University, again highlights the value and importance of mapping transgene integration site(s). 

     
    The paper, entitled "Mapping Transgene Insertion Sites Reveals Complex Interactions Between Mouse Transgenes And Neighboring Endogenous Genes”, illustrates the biological impact of the genomic position of transgene integration sites. 

    New Harvard paper on the importance of mapping transgene integration sites
    Read more...
  • Thursday 12 July 2018

    TLA data used in study to determine genetic cause of belted cattle phenotype

    Recently, the University of Munich published a paper about the genetic background of the belted cattle phenotype.

     

    Their conclusions are that, partly based on data generated with the Targeted Locus Amplification technology, a quadruplication on bovine chromosome 3 was identified as the cause of the belted phenotype.

    TLA data used in study to determine genetic cause of belted cattle phenotype
    Read more...
  • Wednesday 13 June 2018

    Cergentis’ CEO invited to present TLA technology at ACTIP meeting in Dusseldorf

    On June 7, our CEO Max van Min attended the ACTIP meeting in Dusseldorf where he had the privilege of being invited to give a presentation, entitled: '’The Targeted Locus Amplification (TLA) technology and targeted complete Next Generation Sequencing of transgenes & integration sites in cell line development and quality control.'’

    Cergentis’ CEO invited to present TLA technology at ACTIP meeting in Dusseldorf
    Read more...
  • Wednesday 9 May 2018

    Press release: Cergentis awarded Horizon 2020 grant to advance TLA-based targeted complete next generation sequencing for cancer companion diagnostics

    Today, Cergentis announced that it secured a > €1.2 million grant from the European Commission’s Horizon 2020 programme for the development of cancer companion diagnostics.

    The funds will be used to optimise and validate the TLA technology for the analysis of (FFPE) tumour biopsies.

    Press release: Cergentis awarded Horizon 2020 grant to advance TLA-based targeted complete next generation sequencing for cancer companion diagnostics
    Read more...
  • Monday 2 April 2018

    Meet us at the Cell Line Development & Engineering Conference in Amsterdam

    From April 23 to April 25, Cergentis will be attending the Cell Line Development & Engineering Conference at RAI in Amsterdam, The Netherlands.

     

    Visit us at booth #51.

    Meet us at the Cell Line Development & Engineering Conference in Amsterdam
    Read more...
  • Tuesday 19 December 2017

    New JAX - Cergentis paper on mouse transgene integration site sequencing

    On December 18th, 2017, a new paper was published by The Jackson Laboratory (Bar Harbor, ME, USA) and Cergentis (Utrecht, The Netherlands) entitled: "Large-scale discovery of mouse transgenic integration sites reveals frequent structural variation and insertional mutagenesis”.

    New JAX - Cergentis paper on mouse transgene integration site sequencing
    Read more...
  • Wednesday 15 November 2017

    Meet us at the Cell Therapy Manufacturing & Gene Therapy Congress next month

    Cergentis is sponsor of the upcoming Cell Therapy Manufacturing & Gene Therapy Congress in Amsterdam between December 5-7. Our CEO Max van Min will present the TLA technology and its applications in the complete genetic characterisation of transgenic gene therapy products.


    Read more...
  • Wednesday 1 November 2017

    Cergentis Pilot Project Program

    The TLA technology provides important advantages for a wide range of applications. To help explore the opportunities TLA presents in the analysis of genes of interest in humans, animals, plants and micro-organisms, Cergentis introduces the Cergentis Pilot Project Program.

    Cergentis Pilot Project Program
    Read more...
  • Wednesday 11 October 2017

    Meet us at the 6th Cell Culture & Bioprocessing Congress in London

    Cergentis is sponsoring the 6th Cell Culture & Bioprocessing Congress in London between November 6-7. Our Sales Manager Bastiaan Bijl will present the TLA technology and its applications in the complete genetic characterisation of transgenic (CHO) cell lines.


    Read more...
  • Thursday 24 August 2017

    Press release: TLA-based haplotyping to improve the quality of prenatal diagnostics

    The University Medical Center Utrecht and Hubrecht Institute have announced the publication in the American Journal of Human Genetics entitled "Sensitive Monogenic Noninvasive Prenatal Diagnosis by Targeted Haplotyping”. The article describes how the use of TLA-based phasing of heterozygous variants of a gene of interest in parents, capture probes-based targeted sequencing of cfDNA from the pregnant mother, and a tailored statistical analysis enables the prediction of fetal gene inheritance.

    Press release: TLA-based haplotyping to improve the quality of prenatal diagnostics
    Read more...
  • Tuesday 8 August 2017

    Taconic Biosciences announces partnership with Cergentis to provide transgene mapping services

    Taconic Biosciences, a global leader in genetically engineered mouse models and associated services, announced it has signed a collaborative agreement with Cergentis to leverage the company's Targeted Locus Amplification (TLA) technology to provide transgene mapping services to its customers.


    Read more...
  • Wednesday 7 June 2017

    Cergentis releases new Application Note on MRD detection

    Cergentis has released a new application note on the use of gene fusion breakpoints for sensitive detection of minimal residual disease (MRD) in pediatric leukaemia and lymphoma. The Targeted Locus Amplification (TLA) technology can be used to detect the exact patient-specific breakpoint of a disease-causing mutation in leukaemia patients. MRD is an indication of a relapse occurring in the patient and is thus a critical parameter for monitoring progress after treatment.

    Cergentis releases new Application Note on MRD detection
    Read more...
  • Monday 15 May 2017

    Meet us at Cell Line Development & Engineering in San Diego in June

    Cergentis will be attending the Cell Line Development & Engineering Conference in San Diego, CA from June 5 to June 7. Brian Mickus, of Gilead Sciences, will give a presentation, entitled "TLA Targeted Sequencing for De-Risking and Accelerating Clone Selection", on June 6, at 2:45 PM at the Cell Line Development & Engineering stream of the conference.

    Meet us at Cell Line Development & Engineering in San Diego in June
    Read more...
  • Tuesday 4 April 2017

    Meet us at BPI in Amsterdam this month

    Cergentis is sponsor and attendee at the Bioprocessing International (BPI) conference in Amsterdam, between 24 and 26 April 2017.

    Meet us at BPI in Amsterdam this month
    Read more...
  • Friday 10 March 2017

    Meet us at the 5th Plant Genomics & Gene Editing Congress

    On March 16 and 17, the 5th European Plant Genomics & Gene Editing Congress will take place in Amsterdam. Cergentis’ CEO, Max van Min, will give a presentation about the Targeted Locus Amplification (TLA) technology and its applications in the complete targeted sequencing of genes of interest, transgenes and integration sites, and gene editing events in plants.

    Meet us at the 5th Plant Genomics & Gene Editing Congress
    Read more...
  • Friday 3 March 2017

    New Nature publication; MSKCC uses TLA to QC CRISPR-mediated genome editing

    On March 3rd, a new paper from the Memorial Sloan Kettering Cancer Center was published in Nature, entitled: Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. The comprehensive paper discusses the targeted CRISPR/Cas9-mediated integration of a CAR transgene into a specific locus. The Targeted Locus Amplification (TLA) technology has been used to sequence and map the AAV integrations.

    New Nature publication; MSKCC uses TLA to QC CRISPR-mediated genome editing
    Read more...
  • Tuesday 28 February 2017

    Oh Transgene, Where Art Thou? Mapping Transgene Insertions

    Taconic Biosciences has written a blog post about TLA-based transgene mapping service, which highlights the importance mapping transgene insertion site(s) in animal models.

    Oh Transgene, Where Art Thou? Mapping Transgene Insertions
    Read more...
  • Tuesday 10 January 2017

    New Genentech - Cergentis paper on mouse transgene integration site sequencing

    On January 3rd, 2017, Genentech (San Francisco, USA) and Cergentis (Utrecht, The Netherlands) published a paper entitled: "Efficient mapping of transgene integration sites and local structural changes in Cre transgenic mice using targeted locus amplification". The paper, published in Nucleic Acids Research, describes the TLA-based analysis of 7 widely used transgenic Cre mouse lines. The Targeted Locus Amplification (TLA) technology was used to map the integration sites of the transgenes.

    New Genentech - Cergentis paper on mouse transgene integration site sequencing
    Read more...
Previous posts
© 2012-2018 Cergentis B.V. All rights reserved.
For Research Use Only.Not for use in diagnostic procedures.
We use cookies for website analysis and marketing. By visiting and using our website you accept these cookies.
ACCEPT